RE: Official live update of spread of COVID19
July 20, 2021 at 9:45 pm
(This post was last modified: July 20, 2021 at 9:49 pm by brewer.)
Meissa Vaccines’ intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting. The caveat is that the data is from preclinical, non-human primate studies.
The data – also published on bioRxiv – indicates that the MV-014-212 vaccine-induced mucosal (nasal IgA) antibodies in the upper respiratory tract and systemic (serum neutralizing and binding IgG antibodies) in African green monkeys and provided protection when challenged by the wild-type SARS-CoV-2 virus. In vitro, the serum antibodies were also able to neutralize the Alpha (UK) and Beta (South African) viral variants.
Mariana Tioni, Ph.D., presenting the data for the group of 21 researchers, indicated the vaccine “reduced the peak shedding (of) SARS-CoV-2 in the nose by more than 200-fold.” Moreover, she reported approximately 100-fold more spike-specific total serum IgG in the African green monkeys that were vaccinated with MV-014-212 than those that received a mock inoculation, and an 8-fold increase in IgA concentration 25 days after vaccination.
The company is optimistic that these results will carry forward into the Phase I human trial for MV-014-212, for which dosing has begun. That confidence is based upon results from its lead vaccine candidate for RSV, which uses the same delivery platform, AttenuBlock™.
https://www.biospace.com/article/meissa-...y-studies/
The data – also published on bioRxiv – indicates that the MV-014-212 vaccine-induced mucosal (nasal IgA) antibodies in the upper respiratory tract and systemic (serum neutralizing and binding IgG antibodies) in African green monkeys and provided protection when challenged by the wild-type SARS-CoV-2 virus. In vitro, the serum antibodies were also able to neutralize the Alpha (UK) and Beta (South African) viral variants.
Mariana Tioni, Ph.D., presenting the data for the group of 21 researchers, indicated the vaccine “reduced the peak shedding (of) SARS-CoV-2 in the nose by more than 200-fold.” Moreover, she reported approximately 100-fold more spike-specific total serum IgG in the African green monkeys that were vaccinated with MV-014-212 than those that received a mock inoculation, and an 8-fold increase in IgA concentration 25 days after vaccination.
The company is optimistic that these results will carry forward into the Phase I human trial for MV-014-212, for which dosing has begun. That confidence is based upon results from its lead vaccine candidate for RSV, which uses the same delivery platform, AttenuBlock™.
https://www.biospace.com/article/meissa-...y-studies/
I don't have an anger problem, I have an idiot problem.